Biotechnology & Pharmaceutical Opportunities in Singapore

An Expert's View about Biotechnology in Singapore

Posted on: 4 Oct 2010

Singapore aims to grow its BMS output to £12.5 billion by 2015, which is well on track with ongoing public and private sector investment.

Sector briefing Biotechnology & Pharmaceutical Opportunities in Singapore Why Singapore? Singapore embarked on its Biomedical Sciences (BMS) initiative in 2000 to develop the pharmaceuticals, biotechnology, medical technology and healthcare sectors, as part of its move to a knowledge based economy. Since then, the BMS sector has grown rapidly, and it is now the second-largest manufacturing cluster, with nearly 90% of the output from pharmaceuticals, followed by medical devices. The manufacturing sector contributes to a quarter of Singapore?s economy. Singapore aims to grow its BMS output to Singapore aims to grow its £12.5 billion by 2015, which is well on track Biomedical Sciences output to with ongoing public and private sector investment. £12.5 billion by 2015. Singapore was rated among the world?s top 5 biotech spots by Fiercemonitor, in 2007. Find general information on the Singapore market conditions on UKTI?s website. The Doing Business Guide for Singapore gives an overview of Singapore?s economy, business culture, potential opportunities and an introduction to other relevant issues. UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore asset investments reached £0.6 billion in 2009. Opportunities Following large scale investment from API manufacturers, Singapore is now focusing on The BMS sector is driven by two key bodies, biologics, and has attracted US$2 billion worth the Agency for Science, Technology and of investments in the last four years, for 6 new Research (A*STAR), and the Economic plants. Development Board (EDB), with high level advisory committees to chart its course. The A number of pharmaceutical MNCs also have biomedical city, Biopolis, now in its phase IV, their Asia Pacific HQ in Singapore. Besides locates public and private R&D centres, while sales, marketing and distribution, they also Tuas Pharma Park offers shared facilites for undertake R&D, and six new R&D bases were pharmaceutical manufacturers. A medical established in 2009. They also partner technology cluster in the west will be Singapore?s multi-disciplinary scientific and developed to accelerate its growth. clinical network to develop new drugs and therapies. There are now 12 global pharmaceutical and biotechnology companies in Singapore who have invested in over 25 commercial- Biotechnology manufacturing facilities. Another seven plants are set to open in the next three years. The Considerable investment has been made to BMS sector is predicted to grow between 5 - nurture and grow the sector. While BMS Phase 10% in 2010. 1 focused on basic science, Phase 2 is oriented towards moving research from the bench to A brief overview of the main sectors of activity the bedside. Much of the research is centred in will highlight some potential opportunities: the public sector research institutes, who collaborate with universities and hospitals, in their translational medicine efforts. The main R&D areas of research are stem cells, oncology, immunology, neurology, metabolic disorders, A new national research structure was set up in and infectious diseases. The research institutes 2006, with the Research, Innovation and are helmed by renowned international Enterprise Council chaired by the Prime scientists and are staffed by skilled local and Minister, under the new National Research international scientists. Foundation. NRF has a budget of £2.5 billion over 5 years for 3 targeted sectors: biomedical There is a growing number of local biotech sciences, environment and water technologies, companies involved in stem cell research, drug and interactive and digital media. R&D funds discovery and diagnostics. from NRF, A*STAR and the Ministry of Health are primarily for research into areas such as oncology, eye diseases, infectious diseases, Medical Technology and medical devices. Other R&D programmes to spur life sciences research include The There are around 60 medtech companies, Translational Clinical Research programme run mainly MNCs, manufacturing a range of by the National Medical Research Council, and products such as syringes, catheters, hearing the Clinician-Scientist Award, among others. aids, contact lenses, stents, pace makers, research instruments and scientific analytical There are over 4,300 researchers engaged in equipment. Several leverage on the scientific BMS R&D in 50 companies and 30 public sector and engineering capabilities available in institutes, with an annual R&D budget of Singapore to develop innovative and cost around £0.5 billion. effective products for the Asian markets. Singapore accounts for 10% of the world?s Pharmaceuticals supply of contact lenses, half of the world?s thermal cyclers, and over 50% of the world?s Leading pharmaceutical companies such as micro arrays. The medtech industry GlaxoSmithKline, Merck Sharp & Dohme, manufacturing target is £2.5 billion by 2012. Schering-Plough, Wyeth, Pfizer, Abbott, There is also a strong supporting local industry Novartis, Lonza have set up large scale in electronics and precision manufacturing. manufacturing facilities in Singapore. Fixed UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore In a concerted effort to grow the medtech If you have any questions on the opportunities industry, $36 million was allocated for above, contact the UKTI contacts named in this scientists to work with universities and report. Business opportunities aimed hospitals to develop medical devices such as specifically at UK companies are added daily to heart stents, pacemakers, diagnostics for UKTI?s website. These leads are sourced by our stroke and glaucoma, better catheters etc. $20 staff overseas in British Embassies, High million was awarded for research projects in Commissions and Consulates, across all sectors November 2009. and in over 100 markets. You can be alerted to business opportunities on Clinical Trials a regular basis by registering on the UKTI website. Find out more on UKTI?s business The Asian clinical trial market is expected to opportunities service on the UKTI website grow by 20%, and Singapore aims to be the regional centre for clinical trials and drug development. Major CROs such as Quintiles, Covance, MDS Pharma, PPD, Icon etc are established and expanding in Singapore, to address the growing Asian market. Singapore offers a strategic location in Asia to access a diverse patient base, efficient logistics, Government commitment to the life sciences sector, skilled investigators and manpower, and a good regulatory environment to ensure patient safety during clinical trials. Singapore was ranked as one of the most competitive countries globally for conducting world class research in a 2006 survey by KPMG, the only Asian country besides Japan. Upcoming Projects The BMS landscape in Singapore is dynamic and continues to draw in new players while current companies expand their footprint. Some recent developments include: ? Six new biologics manufacturing facilities at around £1 billion to open from 2011 onwards. ? New/expansion of pharmaceutical plants ? New research labs by pharmaceutical manufacturers and medical devices companies ? New regional headquarters by MNCs for the Asia Pacific market. ? New plants by cardiac products manufacturers. ? New set ups and expansion by clinical trials companies ? New set ups by international companies that supply a range of products, equipment and services to the entire BMS industry. UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore Major events and activities UKTI contacts Biopharma Asia Conference & Exhibition Ms Valsa Panicker www.terrapinn.com/2010/biopharmaasia Senior Trade & Investment Attache Contact: Mina Joshi British High Commission Singapore Email: Mina.Joshi@ukti.gsi.gov.uk Tel: (0065) 64244 200 Time: 28 ? 31 March 2011 Email: Valsa.Panicker@fco.gov.uk www.ukti.gov.uk Interphex Asia Exhibition www.interphexasia.com Sarah Croft Contact: Valsa Panicker First Secretary Email: Valsa.Panicker@fco.gov.uk British High Commission Singapore Time: 6-8 June 2010 Tel: (0065) 64244 200 Email: Sarah.Croft@fco.gov.uk Medtech Manufacturing 2011 www.ukti.gov.uk www.speta.org Contact: Valsa Panicker Email: Valsa.Panicker@fco.gov.uk Time: 23 ? 26 March 2011 Find full details of all events in this country and sector on the UKTI website. New export events are added daily to the site and you can register to be alerted to them on a daily, weekly or monthly basis UKTI?s Tradeshow Access Programme (TAP) provides grant support for eligible Small & Medium Sized Enterprises (SME's) to attend trade shows overseas. Find out more about UKTI support for attendance at overseas events UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore Next steps - How UKTI can help ? Arranging appointments British companies wishing to develop their ? Organise seminars or other events for business in the Singapore market are advised you to meet contacts and promote your to undertake as much market research and company in the Chinese market planning as possible in the UK. UKTI?s team in Singapore, with its wide local knowledge and This work is available via our Overseas Market experience, can provide a range of services to Introduction Service (OMIS) a chargeable British-based companies wishing to grow their service which assists British-based companies business in global markets. wishing to enter or expand their business in overseas markets. This can include: ? Provision of market information To find out more about commissioning this ? Validated lists of agents/distributors work, or accessing other UKTI services and ? Key market players or potential specialist advice, please visit the UKTI website customers in the Chinese market to find contact details for your local UKTI ? Establishment of interest of such office. contacts in working with you Whereas every effort has been made to ensure that the information given in this document is accurate, neither UK Trade & Investment nor its parent Departments (the Department for Business, Innovation & Skills, and the Foreign & Commonwealth Office), accept liability for any errors, omissions or misleading statements, and no warranty is given or responsibility accepted as to the standing of any individual, firm, company or other organisation mentioned. Published 2010 by UK Trade & Investment. Crown Copyright © UK Trade & Investment Sector briefing: Biotech & Pharmaceutical opportunities in Singapore
Posted: 04 October 2010

See more from Biotechnology in Singapore

Expert Views    
Biotechnology & Pharmaceutical Opportunities in Singapore   By UK Trade & Investment
Biotechnology & Pharmaceutical Opptys   By UK Trade & Investment
Healthcare Sector   By UK Trade & Investment